Neurodegenerative Diseases

The molecule acts on a protein called BAX, which is central to the process of killing cells by targeting their mitochondria — the component responsible for providing them with energy.

Suven Life secures neuro drug patent from Australia

The company has been granted one product patent from Australia corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases, it said in a BSE filing.

Suven Life shares up 5% on patents in Canada, Europe & Hong Kong

With these new patents, Suven has a total of 24 granted patents from Canada, 22 from Europe and 21 from Hong Kong.

Suven Life secures 2 product patents in Israel & Mexico; up 3%

The company has been granted one product patent from Israel and one product patent from Mexico corresponding to the new chemical entities for the treatment of disorders associated with Neurodegenerative diseases.

Suven Life gets patents for neuro-degenerative drug

In a BSE filing today, Suven Life said it has beengranted "one product patent from Israel and one product patent from Mexico corresponding to the New Chemical Entities (NCEs)for the treatment of disorders associated withNeurodegenerative diseases".

Suven Life jumps 3% on patents in Canada, ARIPO, South Korea

"Suven announced today that grant of one product patent each from Canada, ARIPO and South Korea corresponding to new chemical entities for treatment of disorders associated with neurodegenerative diseases," says the biopharmaceutical company in its filing.

Suven Life rises 5% on product patents in Europe, Macau

"Suven announced that grant of one product patent from Europe and one patent from Macau corresponding to new chemical entities for treatment of disorders associated with neurodegenerative diseases," says the Hyderabad-based biopharmaceutical company in its filing.

Suven Life gets patents for neurodegenerative drug

In a BSE filing, the company said it has been granted "two product patents from Canada and one product patent from China corresponding to their New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases." These patents are valid through 2029 and 2030, the company added.

Suven Life rises 6% on 3 product patents in Canada, China

With these new patents, Suven has a total of 20 granted patents from Canada and 18 granted patents from China.

Suven Life Sciences gets patents for neurodegenerative drug

Biopharmaceutical firm Suven Life Sciences on Tuesday said it has been granted one patent each by the US, Israel and Macau for a drug used in the treatment of neurodegenerative diseases.

Suven Life Sciences gets patents for neurological drug

Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's. In a BSE filing, the company said it has been granted "one product patent from Europe and one product patent from Hong Kong corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases".

Suven Life up 9% on product patents in Canada, Japan, Korea

Shares of Suven Life Sciences rallied 8.6 percent intraday Tuesday on getting three product patents for NCEs in Canada, Japan and Korea.

Suven Life up 5%, gets product patent in Eurasia & Israel

Shares of Suven Life Sciences (Suven) climbed 5 percent intraday Monday on getting product patent each in Eurasia and Israel.

Suven Life Sciences gets patents for neurodegenerative drug

The company said it has been granted one product patent from Australia, two product patents from Japan and one product patent from Hong Kong corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases.

Suven gains 6% on product patents in Eurasia, Japan, Mexico

These patents are corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2029, said the pharma company in its filing to the exchange.

Suven Life soars 7%, gets 5 product patents in 4 countries

Suven today received the two product patents from Israel, one product patent each from Japan, China and New Zealand corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.

Suven Life Sciences up 5%, gets patents in South Korea, US

These patents are related to the new chemical entity (NCE) for the treatment of disorders associated with neurodegenerative diseases and are valid through 2030.

Will need 3-4 years for new patents' materialisation: Suven

Suven Life Sciences secured three product patents (two from Eurasia and one from Canada) corresponding to the new chemical entities for the treatment of disorders associated with Neurodegenerative diseases. The patents are valid through 2027. The company's stocks rallied 5% on the news.

Suven Life gets four patents for new chemical entities

Suven Life Sciences has received four product patents for their new chemical entities (NCE) for treatment of disorders associated with neurodegenerative disorders like Alzheimer’s, Attention Deficit Hyperactivity Disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.

Suven gets 4 product patents for several key markets

Suven Life Science Monday said it has got product patent for its new chemical entity, 5-HT compounds used to treat neurodegenerative diseases like Parkinson and Schizophrenia from Europe, New Zealand, Australia and Korea.